Sean D. Sullivan

About

Sean D. Sullivan is a Professor of Pharmacy at the University of Washington School of Pharmacy and a Visiting Professor at the London School of Economics and Political Science. He holds a joint appointment as Professor of Health Services in the School of Public Health. Dr. Sullivan completed his pharmacy training at Oregon State University in 1983, earned a master's degree from the University of Texas in 1986, and obtained a PhD in health economics and policy from the University of California, Berkeley in 1992. His research interests include pharmaceutical policy, health technology assessment, medical decision-making, and economic evaluation of medical technology, including pharmaceuticals. He has authored more than 450 articles, book chapters, and reports, many assessing the evidence and applications of medical technology in relation to coverage and reimbursement decisions. Dr. Sullivan has held leadership roles such as past president of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and past chair of the Academy of Managed Care Pharmacy (AMCP) Executive Committee of the Format for Formulary Submissions. He has served on various advisory committees, including the Medicare Evidence Development and Coverage Advisory Committee, and has received awards such as the 2014 Stephen G. Avey Lifetime Achievement Award from AMCP and the 2015 APhA Research Achievement Award. In 2020, he was elected to the National Academy of Medicine, and in 2022, he was…

Research topics

• Medicine
• Internal medicine
• Political Science
• Psychiatry
• Oncology
• Endocrinology
• Demography
• Medical education
• Environmental health
• Psychology

Selected publications

• Prevalence and Population-Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study

  American Journal of Respiratory and Critical Care Medicine · 2020 · 108 citations

  Although smoking remains the most important risk factor for CAO, in some areas, poor education, low body mass index, and passive smoking are of greater importance. Dusty occupations and tuberculosis are important risk factors at some sites.

  DOI

• Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States

  Journal of Managed Care & Specialty Pharmacy · 2022 · 75 citations

  Senior authorCorresponding

  Financial support for this research was provided by Novo Nordisk Inc. The study sponsor was involved in several aspects of the research, including the study design, the interpretation of data, the writing of the manuscript, and the decision to submit the manuscript for publication. Dr Kim and Ms Ramasamy are employees of Novo Nordisk Inc. Ms Kumar and Dr Burudpakdee were employees of Novo Nordisk Inc at the time this study was conducted. Dr Sullivan received research support from Novo Nordisk In…

  DOI

• The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer

  Journal of Managed Care & Specialty Pharmacy · 2020 · 20 citations

  Senior authorCorresponding

  BACKGROUND: Larotrectinib and entrectinib are FDA-approved therapies for patients with non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase gene fusion (TRK fusion-positive) whose cancer has metastasized and progressed. Early evidence indicates that these targeted therapies may offer dramatic survival benefits versus traditional cytotoxic regimens, but it remains uncertain how larotrectinib and entrectinib compare with each other. OBJECTIVE: To simulate and compare expec…

  DOI

• The Price Effects of Biosimilars in the United States

  Value in Health · 2025-03-04 · 14 citations

  articleSenior author
  PublisherDOI

• Drug Prices Negotiated by Medicare vs US Net Prices and Prices in Other Countries

  JAMA · 2024-12-02 · 12 citations

  articleOpen access

  This study analyzes how prices negotiated by Medicare in the US compare with net prices before negotiation, ceiling prices, and list prices in 6 other high-income countries.

  PublisherOA PDFDOI

Recent grants

• NIH Grant RC2CA148433

  NIH · $2.0M · 2011

• NIH Grant UC2CA148433

  NIH · $2.0M · 2012

• NIH Grant UC1HS015319

  NIH · $988k · 2007

Frequent coauthors

• Scott D. Ramsey

  University of Washington

  181 shared

• Judy Powell

  81 shared

• Greg C. Larsen

  Lawrence Livermore National Laboratory

  81 shared

• Anna Olarte

  Oregon Health & Science University

  81 shared

• Michael A. Brodsky

  Mayo Clinic in Florida

  81 shared

• John H. McAnulty

  81 shared

• Toshio Akiyama

  81 shared

• Cheryl Jennings

  81 shared

Labs

• Plein Center for AgingPI

Education

• B.S., Pharmacy

  Oregon State University

  1983

• M.S., Pharmacy

  University of Texas

  1986

Awards & honors

• 2014 Stephen G. Avey Lifetime Achievement Award from the Aca…
• 2015 APhA Academy of Pharmaceutical Research Sciences (APRS)…
• Elected Fellow, American Association for the Advancement of…
• Elected to the National Academy of Medicine (2020)

Similar researchers at University of Washington

• Jing Lih-153
• Jan Hansenh-130
• Ruth Etzionih-91